Clinical Trials Logo

Cicatrix, Hypertrophic clinical trials

View clinical trials related to Cicatrix, Hypertrophic.

Filter by:

NCT ID: NCT05461157 Enrolling by invitation - Wound Heal Clinical Trials

Preoperative Silicone Ointment and Wound Healing

Start date: November 14, 2022
Phase: N/A
Study type: Interventional

Optimal scar healing is of great importance to patients, especially following surgery of the head and neck. This study evaluates the effectiveness of preoperative silicone ointment in wound healing in head and neck surgeries.

NCT ID: NCT05434897 Not yet recruiting - Hypertrophic Scar Clinical Trials

A Study to Evaluate the Safety, Tolerability and Efficacy of AK3280 Cream on Hypertrophic Scar

Start date: July 2022
Phase: Phase 1/Phase 2
Study type: Interventional

A randomized, double-blind, placebo self-controlled phase I/II clinical study to evaluate the safety, tolerability and preventive efficacy of different doses of AK3280 cream (AK3287 ) after cicatrectomy in Patients with Hypertrophic Scar in China.

NCT ID: NCT05429411 Recruiting - Burn Scar Clinical Trials

Nonsilicone Gel Sheet for Burn Hypertrophic Scars

Start date: April 22, 2016
Phase: N/A
Study type: Interventional

Overview: The application of gel sheets holds promise for both the prevention and treatment of hypertrophic scar after deep dermal injuries. Although some positive results have been published, a Cochrane review of the data concluded that the trials were of poor quality therefore only provided weak evidence for their benefit. One of the limitations of previous studies has been the subjectivity and potential bias of the evaluation tools that were used. The validation of electronic instrumentation for the measurement of hypertrophic scar and determination of their superior clinometric properties provides the basis from which precise, systematic, evaluations can now be performed that will allow for confident conclusions to be made. Thus, the objective of this study is to evaluate the efficacy of a non-silicone gel sheet relative to a patient-matched control site in a prospective, randomized, controlled, within-patient study. This study has been piloted and the data used to establish the number of participants that will be required for an adequately powered study. Specific Objectives: 1. To characterize the changes in vascularity, thickness, pain and itch in adult burn hypertrophic scar (HSc) following an extended course of treatment with a non-silicone based gel sheet relative to matched control scars. 2. To characterize the changes in pliability of adult burn HSc following an extended course of treatment with a non-silicone based gel sheet relative to matched control scars. Recruitment: Burn survivors aged 14 years and more, who have developed HSc and are being treated at CHUM and Villa Medica Rehabilitation Hospital. Risks: There is a minimal risk that the gel used in this project might cause minor redness (10-25% if the use instructions are not followed). The rash quickly resolves once the gel sheet is removed. Study Site: This study will be carried out at Villa Medica Rehabilitation Hospital.

NCT ID: NCT05423613 Recruiting - Burn Scar Clinical Trials

Microneedling for Burn Hypertrophic Scars

Start date: January 22, 2021
Phase: N/A
Study type: Interventional

Approximately 33 to 91% of severe burn victims will develop hypertrophic scars. Hypertrophic scars are defined as erythematous (red), raised and rigid scars that can cause pain and itching, among other things. They cause psychological distress and affect the quality of life of burn victims. Microneedling is a technique that uses an electrical device to create hundreds of microchannels that penetrate the skin layers. This study is interested in determining the effectiveness of microneedling in improving the pliability, thickness and erythema of hypertrophic scars. Each scar will receive up to 5 ACS-pen treatments followed by the application of cortisone (triamcinolone acetonide). Knowing that microneedling increases the absorption of products applied to the skin by about 80%, it is logical to think that creating these channels to the dermis and applying cortisone afterwards would have a beneficial effect on the hypertrophic scars of these patients.

NCT ID: NCT05412745 Completed - Keloid Clinical Trials

Class I Medical Device on Post-surgical Scars

Start date: May 1, 2022
Phase: N/A
Study type: Interventional

To compare the effect of a class I pullulan based medical device containing Allium cepa & HA versus a class I medical device silicone gel on new post-surgical wounds

NCT ID: NCT05259137 Not yet recruiting - Hypertrophic Scar Clinical Trials

Intra-lesional ACE Inhibitor for Treatment of Hypertrophic Scars

Start date: August 2024
Phase: Phase 2/Phase 3
Study type: Interventional

Hypertrophic scarring is a difficult and debilitating condition where one develops excessive scarring after full thickness injury to the skin. This is very common in full thickness burn injury. Currently, there is no reliable treatment of these scars. One of the more effective treatments available is serial intralesional injection of a steroid. Angiotensin II is an active peptide in the body that results in vasoconstriction of the blood vessels when activated. Medications used today like angiotensin II receptor blocks and angiotensin converting enzyme inhibitors work to prevent the activation of angiotensin II and are mainly used to help control blood pressure. Previous studies in rat models have shown that angiotensin II receptor blockers can effectively reduce scar hypertrophy. In this study, the investigators will conduct a randomized control trial with a paired split-scar design. One arm receiving the standard therapy of serial intra-lesional injections of triamcinolone acetonide (TAC) and the second arm receiving an ACE-inhibitor. The outcome will be measured using the Patient and Observer Scar Assessment Scale (POSAS), a validated assessment tool.

NCT ID: NCT05196373 Not yet recruiting - Hypertrophic Scar Clinical Trials

Safety, Tolerability, Pharmacokinetics, Immunogenicity and Efficacy of STP705 in Adult Patients With Hypertrophic Scars

Start date: June 2023
Phase: Phase 1/Phase 2
Study type: Interventional

Adult patients with hypertrophic scars 30 Subjects in Dose Escalation 20 Subjects in Dose Expansion Intrascar injection of STP705 weekly for 4 weeks

NCT ID: NCT05108272 Recruiting - Hypertrophic Scar Clinical Trials

Comparison of Cosmetic and Functional Outcome of Silicone Sheeting and Micro-needling on Hypertrophic Scars

Start date: July 1, 2021
Phase: N/A
Study type: Interventional

Hypertrophic scars and keloids are frequently encountered in plastic surgery OPD. due to any reason, the normal wound healing is impaired, hypertrophic scars or keloids occur. These are thickened, wide and raised scars. Many treatment options are presented over time, but most of the treatments remain insufficient. Treatment options include massage therapy, silicone sheet, occlusive dressings, pressure garments, adhesive tape, intra-lesional steroid injections, laser therapy, cryotherapy, radiotherapy, 5-fluorouracil, interferons, bleomycin, imiquimod 5%cream, tranilast, botulin toxin and surgical excision. In this Study outcomes of treatment with silicone sheeting and microneedling will be compaired.

NCT ID: NCT05004779 Not yet recruiting - Hypertrophic Scar Clinical Trials

Regenerative Effects of Human Stem Cell Media After Laser Therapy in Hypertrophic Scar

Start date: August 10, 2021
Phase: N/A
Study type: Interventional

The purpose of this study was to determine the effect of combined treatment using nonablative laser and human stem cell media (HSCM) on the regeneration of hypertrophic scars that occurred after burns.

NCT ID: NCT04995302 Not yet recruiting - Burn Scar Clinical Trials

Microneedling Therapy With or Without Amnion Bilayer Sheeting on Scar Tissue

Start date: September 1, 2021
Phase: N/A
Study type: Interventional

The aim of this study is to compare the outcome of microneedling therapy with or without amnion bilayer sheeting on post-burn hypertrophic scar tissue. A clinical trial will be conducted with 17 samples, from September to December 2021.